# Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis

> **NCT04031066** · PHASE3 · WITHDRAWN · sponsor: **Chiesi Farmaceutici S.p.A.**

## Conditions studied

- Alpha-Mannosidosis

## Interventions

- **DRUG:** Velmanase Alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04031066
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-11
- **Primary completion:** 2021-10-27
- **Final completion:** 2021-12-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Big delay on study activation (approval procedures by IRBs, hospitals contract negotiation) and on enrolment deadline due to CoViD-19; Placebo stock expires November 2021 and new batch not be available for at least one year
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031066, "Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04031066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*